157 related articles for article (PubMed ID: 27281840)
21. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia.
van der Meer AC; Hanna LS
Clin Obes; 2017 Feb; 7(1):54-57. PubMed ID: 27984850
[TBL] [Abstract][Full Text] [Related]
22. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
Haoula ZJ; Walker KF; Powell MC
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
[TBL] [Abstract][Full Text] [Related]
23. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
24. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
25. [Current possibilities of examination and preservative treatment in endometrial hyperplasia].
Kołodziejczak M; Knapp P; Kuźmicki M; Knapp P
Ginekol Pol; 2011 Jul; 82(7):514-9. PubMed ID: 21913429
[TBL] [Abstract][Full Text] [Related]
26. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
27. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
[TBL] [Abstract][Full Text] [Related]
28. Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine system.
Mansour D
Best Pract Res Clin Obstet Gynaecol; 2007 Dec; 21(6):1007-21. PubMed ID: 17544330
[TBL] [Abstract][Full Text] [Related]
29. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
Ørbo A; Arnes M; Lyså LM; Straume B
Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
[TBL] [Abstract][Full Text] [Related]
30. Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
Arnes M; Hvingel B; Orbo A
Anticancer Res; 2014 May; 34(5):2319-24. PubMed ID: 24778038
[TBL] [Abstract][Full Text] [Related]
31. Levonorgestrel-releasing intrauterine system: uses and controversies.
Bahamondes L; Bahamondes MV; Monteiro I
Expert Rev Med Devices; 2008 Jul; 5(4):437-45. PubMed ID: 18573044
[TBL] [Abstract][Full Text] [Related]
32. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain.
Lete I; Cristóbal I; Febrer L; Crespo C; Arbat A; Hernández FJ; Brosa M
Eur J Obstet Gynecol Reprod Biol; 2011 Jan; 154(1):71-80. PubMed ID: 20951492
[TBL] [Abstract][Full Text] [Related]
34. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system.
Ercan CM; Duru NK; Sakinci M; Alanbay I; Karasahin KE; Baser I
Gynecol Endocrinol; 2010 Feb; 26(2):125-8. PubMed ID: 20074021
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
Vereide AB; Kaino T; Sager G; Ørbo A;
Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
[TBL] [Abstract][Full Text] [Related]
36. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
37. Long-acting reversible contraception in adolescents.
Morrell K
J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):407-9. PubMed ID: 23304711
[No Abstract] [Full Text] [Related]
38. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
[TBL] [Abstract][Full Text] [Related]
39. Levonorgestrel-releasing intrauterine device therapy vs oral progestin treatment for reproductive-aged patients with endometrial intraepithelial neoplasia: a systematic review and meta-analysis.
Suzuki Y; Ferris JS; Chen L; Dioun S; Usseglio J; Matsuo K; Xu X; Hershman DL; Wright JD
J Natl Cancer Inst; 2024 May; 116(5):653-664. PubMed ID: 38305500
[TBL] [Abstract][Full Text] [Related]
40. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women.
Hampton NR; Rees MC; Lowe DG; Rauramo I; Barlow D; Guillebaud J
Hum Reprod; 2005 Sep; 20(9):2653-60. PubMed ID: 15905289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]